Adaptive Biotechnologies proposes $250M convertible senior notes offering due 2031
Adaptive Biotechnologies announced a proposed $250 million convertible senior notes offering to repay OrbiMed obligations and fund stock repurchases. Proceeds will enhance financial flexibility and support general corporate purposes and MRD business initiatives.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day